Prof. Dr. Bruno Stieger

Division of Clinical Pharmacology and Toxicology, USZ
Rämistrasse 100
8091 Zürich
Tel. +41 44 634 31 69

Bruno Stieger

Main goals, keywords

Main goals: Physiology and pathophysiology of bile formation, mechanisms of acquired forms of liver disease, mechanisms of drug transporters and transporters for liver function markers; Key words: Liver, bile formation, cholestasis, bile acid, drug, transport

Representative publications

Stieger B, Heger M, de Graaf W, Paumgartner G, van Gulik T
The emerging role of transport systems in liver function tests
Eur J Pharmacol, 675(1-3): 1-5, 2012

Guyot C, Stieger B
Interaction of bile salts with rat canalicular membrane vesicles: evidence for bile salt resistant microdomains
J Hepatol, 55(6): 1368-76, 2011

Stieger B
Role of the bile salt export pump, BSEP, in acquired forms of cholestasis
Drug Metab Rev, 42(3): 437-45, 2010

Leuthold S, Hagenbuch B, Mohebbi N, Wagner CA, Meier PJ, Stieger B
Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters
Am J Physiol Cell Physiol, 296(3): C570-82, 2009

Ismair MG, Häusler S, Stuermer CA, Guyot C, Meier PJ, Roth J, Stieger B
ABC-transporters are localized in caveolin-1-positive and reggie-1-negative and reggie-2-negative microdomains of the canalicular membrane in rat hepatocytes
Hepatology, 49(5): 1673-82, 2009

Treiber A, Schneiter R, Häusler S, Stieger B
Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil
Drug Metab Dispos, 35(8): 1400-7, 2007


Member category

Full member

also affiliated with the

Center for Clinical Research (ZKF), UZH

Centre for Xenobiotic Risk Research (XeRR), UZH